Author of the publication

copy delete add this publication to your clipboard
community post
history of this post
URL
DOI
BibTeX
EndNote
APA
Chicago
DIN 1505
Harvard
MSOffice XML

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors

F. Eskens, N. Steeghs, J. Verweij, J. Bloem, O. Christensen, D. van, J. Ouwerkerk, M. Jonge, J. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom. J.Clin.Oncol., 27 (25): 4169-4176 (2009)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Marco Verweij

Anthonie Johannes Adriaan Verweij

Heinrich J J Mieschendahl

Norbert J J Bock

J J M Ramakers

Other publications of authors with the same name

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studyS. Postel-Vinay, L. Collette, X. Paoletti, E. Rizzo, C. Massard, D. Olmos, C. Fowst, B. Levy, P. Mancini, D. Lacombe and 7 other author(s). Eur J Cancer, 50 (12): 2040-2049 (August 2014)Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumorsF. Eskens, N. Steeghs, J. Verweij, J. Bloem, O. Christensen, D. van, J. Ouwerkerk, M. Jonge, J. Nortier, J. Kraetzschmar and 2 other author(s). J.Clin.Oncol., 27 (25): 4169-4176 (2009)The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a reviewF. Eskens, and J. Verweij. Eur.J.Cancer, 42 (18): 3127-3139 (2006)Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyX. Paoletti, C. Le Tourneau, J. Verweij, L. Siu, L. Seymour, S. Postel-Vinay, L. Collette, E. Rizzo, P. Ivy, D. Olmos and 4 other author(s). Eur J Cancer, 50 (12): 2050-2056 (August 2014)Time-dependent effects of fixed covariates in Cox regressionP. Verweij, and H. van Houwelingen. Biometrics, 51 (4): 1550-1556 (December 1995)Analysis and design of production and control structures.M. Verweij, and A. Zwegers. APMS, volume 114 of IFIP Conference Proceedings, page 171-182. Chapman & Hall, (1996)

BibSonomy

Disambiguation of "Verweij, J."